Business Opportunities
Peregrine Pharmaceuticals and Stason Pharmaceuticals to Pursue Tumor Necrosis Therapy (TNT) Development Pact in Asia.
Read more...
|
 |
Biodefense Government Contract
Learn more about Peregrine's five-year $44.4 million contract with the U.S. Defense Threat Reduction Agency (DTRA) to study PS targeting antibodies as protection against viruses at risk as potential bio-weapons.
|
|
Bio-Manufacturing Capabilities
Peregrine's wholly owned subsidiary Avid Bioservices is a rapidly growing manufacturer of biologics for clients worldwide.
|
|
PS-Targeting Study in Clinical Cancer Research
PS-targeting antibody treatment in combination with radiation doubled survival time and produced long-term cures in a lethal brain cancer model.
Read the abstract here.
For additional information see Peregrine’s press release.
|
|
PS-Targeting Mechanism
New Scientist magazine features Peregrine's bavituximab in an article on host-targeted anti-viral drugs, calling exposed PS "the footprint of viral infections."
|
